National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
حداقل ۰.۱ — حداکثر ۲۰ • واحد: ratio
حداقل ۰ — حداکثر ۴
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low0–1
- Low-Intermediate2–3
- High-Intermediate4–5
- High6–8
The National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) calculator is designed for bedside predicting survival in patients with diffuse large B-cell lymphoma (DLBCL) using age, LDH levels, extranodal involvement, Ann Arbor stage, and ECOG performance status in clinical practice. The resulting score directly guides.
Clinical Guidelines & Evidence
Predicts survival in patients with diffuse large B-cell lymphoma (DLBCL) using age, LDH levels, extranodal involvement, Ann Arbor stage, and ECOG performance status. Developed for the rituximab era with enhanced prognostic discrimination.
Clinical Indication
The National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) is indicated for bedside clinical practice to support Predicts survival in patients with diffuse large B-cell lymphoma (DLBCL) using age, LDH levels, extranodal involvement, Ann Arbor stage, and ECOG performance status. Developed for the rituximab era with enhanced prognostic discrimination.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Should be used at initial diagnosis before treatment initiation.
NCCN-IPI Score = Age points + LDH points + Extranodal sites (1 if yes) + Ann Arbor stage (1 if III/IV) + ECOG status (1 if ≥2) Age: ≤40 (0), >40-60 (1), >60-75 (2), >75 (3) LDH: Normal (0), >1-3× ULN (1), ≥3× ULN (2)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years(years) |
| ldh_ratio | float | Yes | LDH (lactate dehydrogenase) ratio compared to upper limit of normal (ULN). Calculate as: patient's LDH / upper limit of normal(ratio) |
| extranodal_sites | string | Yes | Presence of extranodal disease in major organs (bone marrow, CNS, liver/GI tract, or lung) |
| ann_arbor_stage | string | Yes | Ann Arbor staging for lymphoma |
| ecog_performance_status | integer | Yes | ECOG performance status (0 = Fully active, 1 = Restricted in strenuous activity, 2 = Ambulatory but unable to work, 3 = Limited self-care, 4 = Completely disabled) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low | Low risk |
| 2–3 | Low-Intermediate | Low-intermediate risk |
| 4–5 | High-Intermediate | High-intermediate risk |
| 6–8 | High | High risk |
Evidence-Based References (EBM)
- Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 6;123(6):837-42.
- Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020 Jun 4;135(23):2041-2048.
- Gleeson M, Hawkes EA, Peckitt C, Wotherspoon A, Attygalle A, Sharma B, et al. Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. Br J Haematol. 2021 Feb;192(6):1015-1019.